Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.

Study Overview

• Status: Completed
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: Degarelix 240 mg / 80 mg

Detailed Description

The participants received one or more treatment cycles of seven monthly degarelix doses during the induction period(s). The off-treatment period(s) started when prostate-specific antigen (PSA) ≤4 ng/mL and lasted up to 24 months based on PSA levels. A visit was scheduled on a monthly basis during the induction treatment periods, and every two months during the off-treatment periods. During the off-treatment periods, degarelix treatment was re-initiated when PSA >4 ng/mL. The maximum of degarelix IAD treatment cycles that a participant could receive was limited to three.

• Study Type: Interventional
• Enrollment (Actual): 220
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Brugge, Belgium, 8000
    • Hospital St Jan Brugge
  • Brussels, Belgium, 1070
    • Erasme Hospital, University Clinics of Brussels
  • Brussels, Belgium, 1200
    • University Hospîtal St-Luc
  • Leuven, Belgium, 3000
    • University Hospitals Leuven
• France
  • AMIENS cedex 1, France, 80 054
    • Chu Hopital Sud
  • BORDEAUX cedex, France, 33 076
    • Hôpital Pellegrin
  • CERGY PONTOISE cedex, France, 95 303
    • Centre Hospitalier Rene Dubos
  • CLERMONT-FERRAND cedex 1, France, 63 003
    • Hopital Gabriel Montpied
  • Creteil, France, 94 000
    • Hopital Henri Mondor
  • LILLE cedex, France, 59 037
    • Hôpital Claude Huriez
  • MARSEILLE cedex 05, France, 13 385
    • Hôpital de la Conception
  • Montpellier, France, 34 070
    • Clinique BEAUSOLEIL
  • NANTES cedex 1, France, 44 093
    • CHU Hôtel-Dieu
  • NICE cedex 1, France, 06 002
    • Hopital Pasteur
  • PARIS cedex 14, France, 75 679
    • Hopital Cochin
  • PARIS cedex 20, France, 75 970
    • Hôpital Tenon
  • Paris, France, 75 010
    • Hôpital Saint Louis
  • Paris, France, 75 013
    • CHU Pitié Salpétrière
  • Paris, France, 75 018
    • CHU Bichat
  • Pierre Benite, France, 69 310
    • Centre Hospitalier Lyon Sud
  • Poitiers, France, 86 000
    • CHU Le Milétrie
  • RENNES cedex, France, 35 033
    • Hôpital Pontchaillou
  • STRASBOURG cedex, France, 67 091
    • Hôpitaux Universitaires de Strasbourg
  • TOULOUSE cedex 9, France, 31 059
    • Hôpital de Rangueil
• Germany
  • Bad Schwartau, Germany, 23611
    • Gemeinschaftspraxis Dres. Böhle, Rohde
  • Düsseldorf, Germany, 40255
    • Universitätsklinikum Düsseldorf
  • Erkrath, Germany, 40699
    • Gemeinschaftspraxis - Tagesklinik Dres. Rulf, Langhorst
  • Kempen, Germany, 47906
    • Urologische Gemeinschaftspraxis
  • Kirchheim, Germany, 73230
    • Gemeinschaftspraxis Dres. Rudolph, Wörner
  • Rosenheim, Germany, 83022
    • Facharzt für Urologie
  • Tübingen, Germany, 72076
    • Eberhard-Kars-Universität Tübingen
  • Wertingen, Germany, 86637
    • Facharzt für Urologie
  • Wilhelmshaven, Germany, 26389
    • Praxisgemeinschaft f. Onkologie & Urologie
  • Zwickau, Germany, 08060
    • Praxis für Urologie
• Italy
  • Avellino, Italy, 83100
    • Azienda Ospedaliera S. Giuseppe Moscati
  • Bagno a Ripoli (FI), Italy, 50011
    • Università degli studi di Firenze
  • Messina, Italy, 98122
    • Azienda Policlinico Universitario G. Martino
  • Milano, Italy, 20132
    • Ospedale S. Raffaele
  • Padova, Italy, 35128
    • Universita degli Studi di Padova
  • Roma, Italy, 00168
    • Policlinico Univ. Agostino Gemelli
• Netherlands
  • Almelo, Netherlands, 7609 PP
    • Twenteborg Ziekenhuis
  • Groningen, Netherlands, 9713 GZ
    • Universitair Medisch Centrum Groningen
  • Kerkrade, Netherlands, 6461 AL
    • Atrium MC Kerkrade
  • Leiden, Netherlands, 2334 CK
    • Maatschap Urologie-Diaconessenhuis Leiden
  • Nijmegen, Netherlands, 6525 GA
    • UMC St.Radboud
• Spain
  • A Coruña, Spain, 15006
    • Complexo Hospitalario Universitario A Coruña (CHUAC)
  • Alcalá de Henares, Madrid, Spain, 28805
    • Hospital Universitario Príncipe de Asturias
  • Barcelona, Spain, 08035
    • Hospital Universitario Vall d'Hebron
  • Granada, Spain, 18014
    • Hospital Virgen de las Nieves
  • Madrid, Spain, 28041
    • Hospital Universitario 12 De Octubre
  • Sabadell, Spain, 08208
    • Corporació Sanitària Parc Taulí
  • Valencia, Spain, 46009
    • Instituto Valenciano de Oncologia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Has given written informed consent before any trial-related activity is performed. A trial-related activity is defined as any procedure that would not have been performed during the normal management of the patient.
• Has a histologically confirmed (Gleason graded) adenocarcinoma of the prostate (all stages), and is in need of androgen deprivation treatment.
• Patients with Locally Advanced or Metastatic Prostate Cancer - Screening PSA level (measured at a central laboratory) must be >4 ng/mL and ≤50 ng/mL.
• Patients with Localised Prostate Cancer or Patients with Previous Therapy with Curative Intention and a Rising PSA - PSA doubling time (based on patient records at the trial site) must be <24 months. There is no minimum PSA level required and the maximum PSA must be ≤50 ng/mL.
• Is a male patient aged 18 years or older.
• Has an Eastern Cooperative Oncology Group score of ≤2.
• Has a life expectancy of at least 24 months.

Exclusion Criteria:

• Has had previous or is currently under hormonal management of prostate cancer (surgical castration or other hormonal manipulation, including gonadotropin releasing hormone (GnRH) receptor agonists, GnRH antagonists, anti-androgens, 5-alpha reductase inhibitors and estrogens). However, for patients having undergone prostatectomy or radiotherapy with curative intention, then neoadjuvant/adjuvant hormonal therapy for a maximum duration of 6 months is accepted. This treatment should have been terminated at least 6 months prior to Screening Visit.
• Is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy.
• Has a history of severe uncontrolled asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
• Has hypersensitivity towards any component of the investigational medicinal product.
• Has had cancer within the last five years except prostate cancer and surgically removed basal or squamous cell carcinoma of the skin.
• Has a known or suspected clinically significant liver and/or biliary disease.
• Has a history of or risk factors for Torsades de Pointes
• At time of inclusion receives concomitant medications that might prolong the QT interval.
• Has any clinically significant laboratory abnormalities which in the judgment of the investigator would affect the patient's health or the outcome of the trial.
• Has a clinically significant disorder (other than prostate cancer) including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, or psychiatric disease, and alcohol or drug abuse or any other condition, which may affect the patient's health or the outcome of the trial as judged by the investigator.
• Has severe kidney failure (creatinine clearance <30 mL/min), based on the serum creatinine value at Screening Visit and calculated by Cockcroft-Gault algorithm (only valid in France).
• Has a mental incapacity or language barriers precluding adequate understanding or co operation.
• Has received an investigational drug within the last 28 days preceding Screening Visit or longer if considered to possibly influence the outcome of the current trial.
• Has previously participated in any degarelix trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Degarelix 240 mg / 80 mg	Drug: Degarelix 240 mg / 80 mg; For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.; Other Names: Firmagon; FE200486

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Median and Between Participant Variability of Time to Prostate-specific Antigen (PSA) >4 ng/mL During the First Cycle of Intermittent Androgen Deprivation (IAD) After 7 Monthly Injections of Degarelix Induction Treatment	Blood samples for analyses of serum PSA levels were collected at the Screening Visit, and every two months during the course of the trial, and at the End-of-Trial Visit. Analyses were performed using chemiluminometric immunoassay.	Up to 24 months after end of induction period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage Change in PSA Serum Levels From Baseline to the Last Visit of the Induction Period During the First Cycle of IAD		7 months
Median and Between Participant Variability of Time to Return to Testosterone >0.5 ng/mL (Above Castration Level) During the First Cycle of IAD After 7 Monthly Injections of Degarelix Induction Treatment	Blood samples for analyses of serum testosterone levels were collected at the Screening Visit, Month 4 and 7 of the induction period of Cycle 1 and the corresponding visits of any additional treatment cycles, every two months during the off-treatment period(s), and at the End-of-Trial Visit. Analyses were performed using Liquid-Liquid Extraction and Liquid Chromatography-Mass Spectrometry/Mass Spectrometry.	Up to 24 months after end of induction period
Number of Participants With Testosterone ≤0.5 ng/mL at the Last Visit of the Induction Period During the First Cycle of IAD		7 months
Quality of Life, as Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Module (EORTC QLQ-PR25), During the Induction Treatment and Off-treatment Periods During the First Cycle of IAD	The EORTC QLQ-PR25 employs a modular approach towards assessing cancer patients´ health-related Quality of Life (QoL) and assesses urinary, bowel, and sexual symptoms and functioning, and the side-effects of hormonal treatment. It consists of 25 questions distributed on six domains (number of items per domain, ranges from x to y: urinary symptoms (8, 0-100), bother due to use of incontinence aid (1, 0-100), bowel symptoms (4, 0-100), hormonal treatment-related symptoms (6, 0-100), sexual activity (2, 0-100), and sexual functioning (4, 0-100). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).	Up to 31 months
Sexual Function, as Assessed by the International Index of Erectile Function (IIEF) Scale, During the Induction Treatment and Off-treatment Periods During the First Cycle of IAD	The IIEF scale addresses the relevant domains of male sexual function (i.e. erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction). The IIEF scale is psychometrically sound, and has been linguistically validated in multiple languages. The IIEF scale demonstrates the sensitivity and specificity for detecting treatment-related changes in patients with erectile dysfunction. It consists of the following domains (number of items per domain; ranges from x to y: erectile function (6; 1-30), orgasmic function (2; 0-10), sexual desire (2; 2-10), intercourse satisfaction (3; 0-15) and overall satisfaction (2; 2-10). For all domains, a higher score represents a better sexual function.	Up to 31 months
Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight During One or More Cycles of Degarelix IAD Treatment	This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value during the trial.	Up to 3 x 31 months
Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables During One or More Cycles of Degarelix IAD Treatment	This outcome measure included incidence of markedly abnormal changes in safety laboratory values. The table presents the number of participants with normal baseline and at least one post-baseline markedly abnormal value during the trial. ULN=Upper limit of normal.	Up to 3 x 31 months

Collaborators and Investigators

• Sponsor: Ferring Pharmaceuticals

Publications and helpful links

General Publications

• Abrahamsson PA, Boccon-Gibod L, Morote J, de Jong IJ, Malmberg A, Neijber A, Albers P. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy. Eur Urol Focus. 2017 Oct;3(4-5):470-479. doi: 10.1016/j.euf.2015.12.008. Epub 2016 Jan 22.
• Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A, Montorsi F. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur Urol. 2014 Oct;66(4):655-63. doi: 10.1016/j.eururo.2014.05.037. Epub 2014 Jun 18.

Study record dates

Study Major Dates

• Study Start: December 1, 2008
• Primary Completion (ACTUAL): June 1, 2012
• Study Completion (ACTUAL): July 1, 2013

Study Registration Dates

• First Submitted: December 2, 2008
• First Submitted That Met QC Criteria: December 2, 2008
• First Posted (ESTIMATE): December 3, 2008

Study Record Updates

• Last Update Posted (ESTIMATE): September 3, 2014
• Last Update Submitted That Met QC Criteria: September 2, 2014
• Last Verified: September 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms
• Other Study ID Numbers: FE200486 CS29; 2008-003931-19 (EUDRACT_NUMBER)